Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.

@article{Gillis1997OctreotideLR,
  title={Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.},
  author={Jeremy Gillis and Stuart Noble and Karen L. Goa},
  journal={Drugs},
  year={1997},
  volume={53 4},
  pages={
          681-99
        }
}
Octreotide is a somatostatin analogue: a long-acting release (LAR) formulation of octreotide is designed for once-monthly intramuscular administration. As with native somatostatin, octreotide LAR exerts potent inhibitory effects on the secretion of growth hormone and on various peptides of the gastroenteropancreatic endocrine system. When patients with acromegaly who show a positive response to treatment with subcutaneous octreotide 300 to 600 micrograms/day are switched to octreotide LAR 20 or… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Similar Papers

Loading similar papers…